Article Text
Statistics from Altmetric.com
We read with interest the study by Lee et al 1 showing no difference in risk of hepatocellular carcinoma (HCC) and mortality or liver transplantation (LT) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV). We searched Medline, Embase, Scopus, Web of Science and Cochrane database to identify studies comparing TDF and ETV for prevention of HCC and mortality or LT in CHB patients. A total of 11 studies with 70 860 patients (TDF=20 105 and ETV=50 755) were included in this meta-analysis. We used adjusted HR (aHR) when reported and calculated risk ratios (RR) when adjusted effect sizes were not available. These were pooled separately using random effects model. Six studies compared TDF and ETV in propensity score (PS) matched cohorts (in addition to entire cohorts) which were created by matching two groups based on several variables (table 1) to reduce risk of bias.1–6 We …
Footnotes
Contributors FK and SN initiated the study. FK and MAK conducted search and performed the statistical analysis. FK collected the data. FK and MAK drafted the manuscript. SN and AA reviewed and edited the manuscript. All authors approved the final version of manuscript.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.